ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
59
JAMA announces Rivoceranib's NSCLC combination therapy
admin
2020.04.27
58
Immunomic Therapeutics to initiate developing COVID-19 Vaccine
admin
57
Rivoceranib approved for phase 3 clinical trial as first-line lung cancer treatment
admin
56
Doctor William Hearl appointed as the Director of HLB
admin
55
Elevar Therapeutics announces enrollment of the first patient in a pivotal trial for the treatment of Adenoid Cystic Cancer (AC
admin
54
HLB requests marketing authorization for second-line liver cancer for Rivoceranib
admin
53
HLB's acquisiton of Rivoceranib's global rights
admin
52
HLB takes over Immunomic Therapeutics
admin
51
Elevar Therapeutics acquires Global Rights to European approved Apealea® from Oasmia Pharmaceutical
admin
50
JAMA announces Rivoceranib's NSCLC combination therapy
admin
1
2
3
4
5
6
7
8
9
10
>
>>